All tools
Tools
Peptide stacking safety checker.
Most peptide interactions are mechanistic rather than pharmacokinetic — they overlap on a target system rather than competing for clearance pathways. That changes how you mitigate them. This page catalogs the known peptide-peptide interaction patterns, groups them by severity (avoid, caution, generally safe), and explains the underlying reason so a reader can extend the logic to compounds that aren't on the list yet.
How to use this
- 1Look at the "avoid" section first. These are the pairings most likely to send someone to a clinic. The rest of the table assumes you've cleared the floor.
- 2"Caution" isn't "don't." Most of these are common, working stacks that need spacing or monitoring. Read the reasoning column before assuming a row applies to you.
- 3Absence means "not catalogued," not "safe." If a pair isn't listed, we haven't seen enough clinical or community signal to call it. Default to running one new compound at a time and watching.
Avoid(7)
Published or mechanistic conflict, additive risk that outweighs the benefit.
| Peptide A | Peptide B | Reasoning | Citation |
|---|---|---|---|
| Semaglutide | Tirzepatide | Both are long-acting GLP-1 receptor agonists with ~5-day half-lives. Stacking compounds GI toxicity, gallbladder strain, and pancreatitis risk without meaningful efficacy gain over titrating one to higher dose. | View |
| Retatrutide | Semaglutide | Reta already covers GLP-1 receptor agonism plus GIP and glucagon. Adding sema duplicates GLP-1 activity and amplifies nausea, vomiting, and bradycardia signals. | — |
| Retatrutide | Tirzepatide | Overlapping GLP-1 + GIP coverage with extended half-life on both compounds. Reported additive heart-rate elevation and gastroparesis in community logs. | — |
| Melanotan II | PT-141 (Bremelanotide) | Both are melanocortin receptor agonists. Stacking produces unpredictable BP swings (PT-141's known pressor effect compounded by MT-II vasomotor activity) and amplified nausea. | — |
| CJC-1295 DAC | Tesamorelin | Both are long-acting GHRH analogs. Stacking creates a sustained GH/IGF-1 elevation that pushes past physiologic range — insulin-resistance and tunnel-syndrome signals appear within weeks. | — |
| Ipamorelin | MK-677 (Ibutamoren) | Both act on the ghrelin/GHS-R pathway. MK-677's 24-hour half-life already saturates the receptor — adding a short-acting GHRP just blunts the response (tachyphylaxis) and stacks appetite + water-retention side effects. | — |
| Liraglutide | Semaglutide | Both GLP-1 receptor agonists; lira has a 13-hour half-life and sema 165 hours. Coverage overlap is total, side-effect overlap is total, and there's no protocol justification for using both. | — |
Caution(9)
Used in practice but needs spacing, dose adjustment, or monitoring.
| Peptide A | Peptide B | Reasoning | Citation |
|---|---|---|---|
| CJC-1295 (no DAC) | Ipamorelin | Classic GHRH + GHRP synergy stack. The combo is well-tolerated but pushes IGF-1 enough that long-running protocols (>12 weeks continuous) show insulin sensitivity drift. Cycle, monitor fasting glucose, and consider 5-on/2-off dosing. | — |
| Tirzepatide | Cagrilintide | Amylin + GLP-1/GIP is the published 'CagriSema' direction and works clinically, but the GI side effect floor is higher than either alone. Titrate cagri slowly and don't escalate both simultaneously. | View |
| BPC-157 | TB-500 (Thymosin β4) | Common healing stack. No published interaction, but the additive angiogenic signaling has theoretical concern with active malignancy or proliferative retinopathy. Skip if either is a personal risk factor. | — |
| GHK-Cu | BPC-157 | Both modulate copper-dependent collagen pathways. Stacking is generally fine systemically but topical GHK-Cu over a BPC injection site can interact with the local healing signal — keep at least 6 hours apart at the same site. | — |
| Ipamorelin | Tesamorelin | GHRP + GHRH synergy that's safer than the CJC-DAC + tesa overlap because ipamorelin clears in ~2 hours. Still monitor IGF-1 quarterly on sustained protocols. | — |
| Semaglutide | Cagrilintide | The clinical CagriSema combination. Effective for weight loss but stack-vs-titrate dose escalation must be slow — combined GI side effects can be intolerable if both are ramped at once. | View |
| MOTS-c | Tirzepatide | Both improve glucose disposal through different pathways (MOTS-c at AMPK; tirz via incretin). Combined the user can hypoglycemic if also on insulin or sulfonylureas. Solo or with metformin only. | — |
| Sermorelin | Ipamorelin | Older GHRH (sermorelin) plus modern GHRP. Effective but sermorelin's short half-life means timing matters — co-administer or skip the GHRH dose; spacing them more than 30 minutes apart wastes the synergy window. | — |
| 5-Amino-1MQ | Semaglutide | 5A1MQ is being used to preserve lean mass during GLP-1 cuts. No conflict identified, but the combo can stall weight loss if the user mistakes muscle preservation for plateau and over-titrates the GLP-1. | — |
Generally safe(10)
Community-stacked without known interaction. Standard contraindication checks still apply.
| Peptide A | Peptide B | Reasoning | Citation |
|---|---|---|---|
| BPC-157 | Semaglutide | BPC's gut-protective effect is sometimes used to blunt sema GI side effects. No mechanistic conflict; some users report fewer nausea episodes when BPC is started first. | — |
| BPC-157 | Tirzepatide | Same rationale as the BPC + sema pairing. Independent pathways, no overlap. | — |
| GHK-Cu | Melanotan II | Both used in aesthetic stacks (skin quality + tanning). Different receptors, different timescales, no documented conflict. | — |
| Tesofensine | Semaglutide | Different mechanism (monoamine reuptake inhibition vs. GLP-1). Use of both is uncommon but documented in some weight-loss protocols. Monitor blood pressure given tesofensine's noradrenergic action. | — |
| Selank | Semax | Common Russian-research nootropic stack. Different mechanisms (Selank — GABAergic; Semax — BDNF/melanocortin). No known interaction. | — |
| Dihexa | Cerebrolysin | Both pro-cognitive but operate at different scales (Dihexa at single-synapse HGF, Cerebrolysin as a broad neurotrophic mix). Used together in nootropic protocols without known conflict. | — |
| Thymosin Alpha-1 | TB-500 | Different thymosins entirely despite the naming — Tα1 is immune-modulatory, TB-500 (Tβ4) is tissue-repair. No competition, often run together in long-COVID and post-injury protocols. | — |
| Epitalon | BPC-157 | Epitalon's telomerase activity and BPC's healing signaling are independent. Both commonly run in longevity protocols without known interaction. | — |
| AOD-9604 | BPC-157 | AOD-9604 lipolytic activity is independent of BPC's healing pathway. Co-use is documented in body recomposition protocols without conflict. | — |
| PT-141 (Bremelanotide) | BPC-157 | Independent mechanisms. No documented conflict and no shared receptor activity. | — |
Educational reference only. This page is informational and does not constitute medical advice. Peptide protocols carry real clinical risk. Consult a qualified healthcare provider before reconstituting, injecting, or stacking any compound.
Related tools
Keep going.
Half-life chart
All 80 peptides ranked shortest to longest, with the dosing frequency each half-life implies.
ReadBAC vs sterile water
Which diluent goes in which vial, and why preservative status changes the math.
ReadReconstitution chart
Every common vial size × every common BAC volume × every common dose, pre-computed.
ReadCost-per-mg calculator
Plug in vial size and price — get cost per mg and per dose, plus reference ranges.
Read